Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07943741
PHASE2

Ketamine for Treatment of Alzheimers Disease Related Depression

Sponsor: Vanderbilt University Medical Center

View on ClinicalTrials.gov

Summary

Dementia is one of the major causes of disability and among older adults globally, with 6.7 million Americans living with Alzheimer's disease. Depression is common in people with cognitive and memory problems. Depression in the elderly increases the risk of disability, medical comorbidity, cognitive impairment, and death. Patients with depression are at an increased risk of worsening cognition. Further, patients with depression are traditionally excluded from therapeutic trials in Alzheimer's Disease and other dementias. Current medications to treat depression in patients with dementia haven't been helpful. Effective approaches to treating depression in dementia are necessary. Ketamine has been studied extensively for the treatment of depression. It produces a rapid antidepressant effect with improvement of depressive symptoms reported 2 hours after infusion that continues for several days. Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia and reduce depression burden and improve quality of life and function. As patients with depression are likely unable to receive disease modifying therapies for Alzheimer's Disease (lecanemab or donanemab) rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive these therapies faster. This proposal, will examine the safety, tolerability and feasibility of administering IV ketamine for the treatment of depression in participants with Alzheimer's Disease as well as obtain preliminary data regarding the treatment benefit.

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-12-01

Completion Date

2029-12

Last Updated

2026-11-17

Healthy Volunteers

No

Interventions

DRUG

Ketamine and saline

Ketamine will be infused over 40 min twice weekly for two weeks. Ketamine will be calculated as 0.5mg/kg.

DRUG

Active Placebo (Midazolam) Infusion

Active placebo (midazolam) will be infused over 40 min twice weekly for two weeks. Active placebo (midazolam) dose will be calculated as 0.02mg/kg.

Locations (1)

Vanderbilt Psychiatric Hospital

Nashville, Tennessee, United States